All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-07-08T07:49:21.000Z

FDA calls a stop to Merck’s trials of pembrolizumab in MM

Jul 8, 2017
Share:

Bookmark this article

Following the halt called by an external data monitoring committee to two phase 3 trials testing pembrolizumab (Keytruda)  in patients with MM (as previously reported on the MM Hub), the FDA has now called a complete stop to both studies. The trials were designed to assess the benefit of pembrolizumab in combination with the backbone regimens of dexamethasone and pomalidomide, and lenalidomide and dexamethasone, KEYNOTE-183 and KEYNOTE-185 trials, respectively.

This follows an investigation into a higher than average number of deaths in the test patient population, and the decision was made by the external committee to refuse any further recruits to the trials, although patients already taking pembrolizumab could continue. However, the US Food and Drug Administration (FDA) has now called a complete stop, asking for patients to be taken off pembrolizumab altogether. No further information has been revealed about the exact cause of the deaths, although it has been postulated that lung infections, noted as a side-effect in other trials with pembrolizumab, may be to blame. It appears that an additional phase I study was also put on hold.

Pembrolizumab is a monoclonal antibody and a member of the family of therapies called checkpoint inhibitors, which block proteins involved in immune suppression of cancer cells. Pembrolizumab has been much discussed in reference to MM at recent congresses and was heralded a success after several earlier trials indicated durable responses. This will, therefore, be a severe disappointment for Merck, who already market the drug for use in several other cancers and had hoped to extend the indication to MM. However, the FDA has stated that currently, the benefits do not appear to outweigh the potential risk to patients.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox